Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Core Points - Gain Therapeutics, Inc. has appointed Gene Mack as interim CEO following the departure of Matthias Alder, while Khalid Islam will serve as Executive Chairman until a permanent CEO is found [2] - The company’s lead drug candidate, GT-02287, is in clinical development for Parkinson's disease and has shown significant improvements in cognitive performance in preclinical models [3][4] - GT-02287 functions as an allosteric protein modulator, restoring the function of the glucocerebrosidase enzyme, which is impaired due to GBA1 gene mutations [4] - The drug has demonstrated the ability to reduce neuroinflammation, neuronal death, and increase dopamine levels, alongside lowering plasma neurofilament light chain levels, a biomarker for neurodegeneration [4] - Gain Therapeutics has received funding support for its Parkinson's disease program from notable organizations including The Michael J. Fox Foundation and the Eurostars-2 joint program [5] - The company utilizes an advanced drug discovery platform, Magellan™, which leverages AI and supercomputing to identify novel allosteric binding sites on proteins [7][8] Company Overview - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric therapies [6] - The company’s lead candidate, GT-02287, is currently undergoing a Phase 1 clinical trial [6]